期刊文献+

小剂量氟尿嘧啶对肝癌细胞HepG2生物学行为的影响与^(18)F-FDG摄取关系的研究 被引量:3

Correlation between ^(18)F-FDG uptake and effect of small dose 5-Fu on biological behaviors of liver cancer HepG2 cells
下载PDF
导出
摘要 目的研究小剂量氟尿嘧啶处理肝癌细胞HepG2后部分生物学行为与其摄取氟代脱氧葡萄糖(18F-FDG)变化的关系。方法使用低浓度的5-Fu(1μg/ml)培养肝癌细胞系HepG2,持续培养4周期后(第4周期后细胞简称HepG2/4P),观察细胞形态,绘制生长曲线,计算倍增时间;用Western blot检测Ki67的表达;于体外进行18F-FDG细胞放射性核素摄取实验。结果HepG2与HepG2/4P组的倍增时间分别为16.2h、25.2h;Ki67相对表达量分别为0.367±0.005、0.270±0.019,两组差异有统计学意义(P<0.05);HepG2/4P对18F-FDG摄取率较化疗前HepG2摄取降低,但无统计学意义(P=0.093)。结论HepG2/4P细胞与HepG2相比倍增时间延长,Ki67的表达降低,对18F-FDG摄取降低,提示肝癌细胞增殖的差异可能会引起肿瘤糖代谢相应的差异,可能用于监测化疗疗效和预测细胞生物学行为的改变。 Objective To study the correlation between 18F-FDG uptake and effect of small dose 5-Fu on biological behaviors of liver cancer HepG2 cells.Methods Morphological changes of liver cancer HepG2 cells were observed 4 weeks after they were cultured with 1μg/ml 5-Fu(expressed as HepG2/4P).Then,their growth curve was plotted to calculate the doubling time of their growth.Expression of Ki67 was detected by Western blot.Uptake of 18F-FDG in vitro was detected using radioactive nuclide.Results The doubling time of HepG2 and HepG2/4P was 16.2h and 25.2h,respectively.The expression of Ki67 was 0.367±0.005 and 0.270±0.019,respectively(P0.05).The uptake of 18F-FDG was lower by HepG2/4P than by HepG2(P=0.093).Conclusion The doubling time of HepG2/4P is longer than HepG2 while the expression level of HepG2/4P is lower than that of HepG2 and the uptake of 18F-FDG is lower by HepG2/4P than by HepG2,suggesting that differences in proliferation of liver cancer cells can lead to corresponding differences in glucose metabolism,and uptake of 18F-FDG can be used as an indicator in monitoring chemotherapy and biological behaviors of liver cancer cells.
出处 《军医进修学院学报》 CAS 2010年第6期577-579,共3页 Academic Journal of Pla Postgraduate Medical School
基金 国家自然科学基金项目(30770607)~~
关键词 肝肿瘤 HEPG2 氟尿嘧啶 18F-FDG Liver Neoplasms HepG2 Fluorouracil 18F-FDG
  • 相关文献

参考文献3

二级参考文献17

  • 1谢丽,安瑞芳,王姝,薛艳.Ki-67蛋白在妊娠滋养细胞疾病中表达的意义[J].现代肿瘤医学,2007,15(7):1001-1003. 被引量:3
  • 2M. Galindo Gallego M.D.,M. J. Fernández Ace?ero M.D.,J. Sanz Ortega M.D.,A. Aljama Delgado,J. L. Balibrea Cantero M.D.Prognostic influence of p53 nuclear overexpression in colorectal carcinoma[J].Diseases of the Colon & Rectum.2000(7)
  • 3O. Dworak,L. Keilholz,A. Hoffmann.Pathological features of rectal cancer after preoperative radiochemotherapy[J].International Journal of Colorectal Disease.1997(1)
  • 4WongNA,Brett L,Stewart M,Leitch A,Longley DB,Dunlop MG,Johnston PG,Lessells AM,Jodrell DI.Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma[].Br J Cancer.2001
  • 5HeidelbergerC,Chaudhari N,Danenberg PV.Fluorinate pyrimidines: a new class of tumor-inhibitory compounds[].Nature.1957
  • 6PopatS,Matakidou A,Houlston RS.Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis[].J Clin Oncol.2004
  • 7JakobC,Aust DE,Meyer W,Baretton GB,Schwabe W,Hausler P,Becker H,Liersch T.Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU- based neo-adjuvant chemoradiotherapy in rectal cancer[].J Pathol.2004
  • 8JakobC,Liersch T,Meyer W,Baretton GB,Hausler P,Schwabe W,Becker H,Aust DE.Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant[].Am J Surg Pathol.2005
  • 9JakobC,Liersch T,Meyer W,Baretton GB,Schwabe W,Hausler P,Kulle B,Becker H,Aust DE.Prognostic value ofhistologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy[].Am J Surg Pathol.2006
  • 10AhnenDJ,Feigl P,Quan G,Fenoglio-Preiser C,Lovato LC,Bunn PA Jr,Stemmerman G,Wells JD,Macdonald JS,Meyskens FL Jr.Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study[].Cancer Res.1998

共引文献52

同被引文献12

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部